162 related articles for article (PubMed ID: 10928169)
1. Super-sensitive prostate-specific antigen (PSA) in serum of women with benign breast disease or breast cancer.
Hautmann S; Huland E; Grupp C; Haese A; Huland H
Anticancer Res; 2000; 20(3B):2151-4. PubMed ID: 10928169
[TBL] [Abstract][Full Text] [Related]
2. Measurement of prostate-specific antigen in detection of benign or malignant breast disease in women.
Romppanen J; Keskikuru R; Kataja V; Eskelinen M; Kosma VM; Savolainen K; Uusitupa M; Mononen I
Br J Cancer; 1999 Mar; 79(9-10):1583-7. PubMed ID: 10188910
[TBL] [Abstract][Full Text] [Related]
3. Serum total and free prostate-specific antigen for breast cancer diagnosis in women.
Black MH; Giai M; Ponzone R; Sismondi P; Yu H; Diamandis EP
Clin Cancer Res; 2000 Feb; 6(2):467-73. PubMed ID: 10690525
[TBL] [Abstract][Full Text] [Related]
4. Percent free prostate specific antigen in the total prostate specific antigen 2 to 4 ng./ml. range does not substantially increase the number of biopsies needed to detect clinically significant prostate cancer compared to the 4 to 10 ng./ml. range.
Haese A; Dworschack RT; Partin AW
J Urol; 2002 Aug; 168(2):504-8. PubMed ID: 12131298
[TBL] [Abstract][Full Text] [Related]
5. Prostate-specific antigen in breast disease.
Poh BH; Jayaram G; Sthaneshwar P; Yip CH
Malays J Pathol; 2008 Jun; 30(1):43-51. PubMed ID: 19108411
[TBL] [Abstract][Full Text] [Related]
6. Prospective evaluation of prostate cancer detection by prostate specific antigen related parameters: comparison in serum and plasma samples.
Egawa S; Suyama K; Matsumoto K; Kuwao S; Baba S
J Urol; 2002 Jan; 167(1):97-102. PubMed ID: 11743284
[TBL] [Abstract][Full Text] [Related]
7. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
Suzuki H; Akakura K; Igarashi T; Ueda T; Ito H; Watanabe M; Nomura F; Ochiai T; Shimada H
J Urol; 2004 Jan; 171(1):182-6. PubMed ID: 14665872
[TBL] [Abstract][Full Text] [Related]
8. Is transition zone biopsy valuable in benign prostatic hyperplasia patients with serum prostate-specific antigen >10 ng/ml and prior negative peripheral zone biopsy?
Abdel-Khalek M; Sheir KZ; El-Baz M; Ibrahiem el-H
Scand J Urol Nephrol; 2005; 39(1):49-55. PubMed ID: 15764271
[TBL] [Abstract][Full Text] [Related]
9. Complexed prostate specific antigen improves specificity for prostate cancer detection: results of a prospective multicenter clinical trial.
Partin AW; Brawer MK; Bartsch G; Horninger W; Taneja SS; Lepor H; Babaian R; Childs SJ; Stamey T; Fritsche HA; Sokoll L; Chan DW; Thiel RP; Cheli CD
J Urol; 2003 Nov; 170(5):1787-91. PubMed ID: 14532777
[TBL] [Abstract][Full Text] [Related]
10. Tumor-associated forms of prostate specific antigen improve the discrimination of prostate cancer from benign disease.
Mikolajczyk SD; Rittenhouse HG
Rinsho Byori; 2004 Mar; 52(3):223-30. PubMed ID: 15137320
[TBL] [Abstract][Full Text] [Related]
11. Prostate-specific antigen in the serum of women with benign breast disease.
Radowicki S; Kunicki M; Bandurska-Stankiewicz E
Eur J Obstet Gynecol Reprod Biol; 2008 Jun; 138(2):212-6. PubMed ID: 17850950
[TBL] [Abstract][Full Text] [Related]
12. Preoperative serum caveolin-1 as a prognostic marker for recurrence in a radical prostatectomy cohort.
Tahir SA; Frolov A; Hayes TG; Mims MP; Miles BJ; Lerner SP; Wheeler TM; Ayala G; Thompson TC; Kadmon D
Clin Cancer Res; 2006 Aug; 12(16):4872-5. PubMed ID: 16914574
[TBL] [Abstract][Full Text] [Related]
13. Percent free prostate-specific antigen (PSA) is an accurate predictor of prostate cancer risk in men with serum PSA 2.5 ng/mL and lower.
Walz J; Haese A; Scattoni V; Steuber T; Chun FK; Briganti A; Montorsi F; Graefen M; Huland H; Karakiewicz PI
Cancer; 2008 Nov; 113(10):2695-703. PubMed ID: 18853417
[TBL] [Abstract][Full Text] [Related]
14. Early postoperative peripheral blood reverse transcription PCR assay for prostate-specific antigen is associated with prostate cancer progression in patients undergoing radical prostatectomy.
Shariat SF; Kattan MW; Song W; Bernard D; Gottenger E; Wheeler TM; Slawin KM
Cancer Res; 2003 Sep; 63(18):5874-8. PubMed ID: 14522912
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of serum markers for prostate cancer.
Stenman UH; Abrahamsson PA; Aus G; Lilja H; Bangma C; Hamdy FC; Boccon-Gibod L; Ekman P
Scand J Urol Nephrol Suppl; 2005 May; (216):64-81. PubMed ID: 16019759
[TBL] [Abstract][Full Text] [Related]
16. The biologic lower detection limit of six ultrasensitive PSA assays.
Junker R; Brandt B; Semjonow A; Erren M; Zechel C; Assmann G
Anticancer Res; 1999; 19(4A):2625-8. PubMed ID: 10470206
[TBL] [Abstract][Full Text] [Related]
17. The significance of prostate-specific antigen alpha-1-antichymotrypsin complex and its indices for the detection of prostate cancer.
Yamanaka K; Yamada Y; Kobayashi Y; Ueno K; Takechi Y; Hasegawa E; Chikahira Y
Hinyokika Kiyo; 2003 Jan; 49(1):5-10. PubMed ID: 12629773
[TBL] [Abstract][Full Text] [Related]
18. Differential percentage of serum prostate-specific antigen subforms suggests a new way to improve prostate cancer diagnosis.
Sarrats A; Comet J; Tabarés G; Ramírez M; Aleixandre RN; de Llorens R; Peracaula R
Prostate; 2010 Jan; 70(1):1-9. PubMed ID: 19670261
[TBL] [Abstract][Full Text] [Related]
19. Prostate-specific antigen detection by ultrasensitive assay in samples from women.
Filella X; Molina R; Alcover J; Menéndez V; Giménez N; Jo J; Carretero P; Ballesta AM
Prostate; 1996 Nov; 29(5):311-6. PubMed ID: 8899004
[TBL] [Abstract][Full Text] [Related]
20. [Model of screening for prostatic cancer among patients with prostate specific antigen concentration of 4-10 ng/ml in blood].
Karazanashvili GG; Managadze LG
Urologiia; 2000; (6):37-41. PubMed ID: 11186321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]